Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16 clinical trials
Triple Combination of Pevonedistat and Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy

The purpose of this study is to determine whether the combination of pevonedistat + venetoclax + azacitidine improves event-free survival (EFS) compared with venetoclax + azacitidine in patients

direct bilirubin
myelodysplastic syndromes
ejection fraction
ara-c
gilbert's syndrome
  • 2 views
  • 25 Mar, 2021
  • 49 locations
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS) Chronic Myelomonocytic Leukemia (CMML) or Low-Blast Acute Myelogenous Leukemia (AML)

The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared with single-agent azacitidine. (An event is

induction chemotherapy
myelodysplastic syndromes
chronic myelomonocytic leukemia
azacitidine
pevonedistat
  • 341 views
  • 09 May, 2021
  • 320 locations
Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma

The purpose of this study is to test any good and bad effects of activity pevonedistat taken alone, and also to test the safety of pevonedistat in combination with standard chemotherapy

direct bilirubin
pleural mesothelioma
renal function
chemotherapy regimen
gilbert's syndrome
  • 14 views
  • 26 Jan, 2021
  • 8 locations
Azacitidine Venetoclax and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

This phase I/II trial studies the best dose of venetoclax when given together with azacitidine and pevonedistat and to see how well it works in treating patients with newly diagnosed acute

chronic myelomonocytic leukemia
chromosome abnormality
myeloproliferative disorder
thrombocytosis
essential thrombocythemia
  • 40 views
  • 18 Mar, 2021
  • 1 location
Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

This phase I trial studies side effects and best dose of pevonedistat and belinostat in treating patients with acute myeloid leukemia or myelodysplastic syndrome that has come back (relapsed) or

  • 0 views
  • 21 Apr, 2021
  • 1 location
Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis

Based on the investigators' preclinical data, the combination of pevonedistat and ruxolitinib may provide greater clinical responses in patients with myelofibrosis compared to ruxolitinib

direct bilirubin
ruxolitinib
polycythemia
neutrophil count
conjugated bilirubin
  • 60 views
  • 24 Jan, 2021
  • 1 location
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

This phase I trial studies the side effects and best dose of pevonedistat when given together with ibrutinib in participants with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has

fatigue
marginal zone lymphoma
absolute neutrophil count
richter's syndrome
venetoclax
  • 12 views
  • 24 Jan, 2021
  • 2 locations
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL

The investigators postulate that Pevonedistat will be effective in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) when combined with a standard backbone ALL chemotherapy

  • 14 views
  • 19 Feb, 2021
  • 2 locations
Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS

The investigators hypothesize that the combination of Pevonedistat/Low-Dose Cytarabine (LDAC) therapy will be tolerable, that a recommended phase 2 dose of Pevonedistat in combination with LDAC

direct bilirubin
myelodysplastic syndromes
decitabine
blood transfusion
gilbert's syndrome
  • 21 views
  • 26 Jan, 2021
  • 1 location
Pevonedistat Azacitidine and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia

This is a phase Ib study with a 3 + 3 dose escalation design followed by a dose-expansion phase.

direct bilirubin
induction chemotherapy
venetoclax
secondary acute myeloid leukemia
azacitidine
  • 2 views
  • 05 Feb, 2021
  • 2 locations